From October 22 to 25, 2025, the 46th National Conference on the publication of papers on quality management (QCC) in the pharmaceutical industry, hosted by the China Pharmaceutical Quality Management Association, was successfully concluded in Fuzhou. With excellent professionalism and rigorous and pragmatic attitude, the participating team of Leecan Pharmaceutical Co., Ltd. carried out the quality concept of "keeping improving" from the precise topic selection to the on-site defense, and won the high recognition of the conference!
In this conference, Leecan pharmaceutical won three awards: the "Ruijia" QC team of the technology department won the first prize and the best publication award with the topic of "reducing the rejection rate of lamp inspection of variety a"; The "Bicheng" QC team of the QC department also won the first prize and the best publication Award for the subject of "improving the ability index of the total amount detection method of the child mode delivery of variety a"; The "Rio Tinto" QC team of the production department won the first prize for the subject of "improving the yield of finished products of line B a". This is the first time that Leecan Pharmaceutical Co., Ltd. participated in the 45th exchange meeting in 2024 and won the first prize for both topics. Leecan Pharmaceutical Co., Ltd. has continued to make good achievements this year, further demonstrating the company's deep strength in quality management and continuous improvement.
We applaud the partners who participated in this exchange meeting and pay tribute to all colleagues who are deeply engaged in the pharmaceutical industry! As a modern and innovative pharmaceutical enterprise, Leecan pharmaceutical is continuously deepening its efforts in the field of high-end complex and innovative preparations, driving the enterprise towards a new pattern of high-quality development with technological innovation, and constantly promoting the quality level of Chinese medicine with the professionalism of "pharmaceutical people"!
025-58181716
Share:
